Literature DB >> 10086337

Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion.

B Valentinis1, A Morrione, F Peruzzi, M Prisco, K Reiss, R Baserga.   

Abstract

The type 1 insulin-like growth factor receptor (IGF-IR) is known to protect cells from a variety of apoptotic injuries. In several instances, the anti-apoptotic effect of the wild type IGF-IR is more evident under conditions of anchorage-independence than in cells in monolayer cultures. We have investigated IGF-IR signaling in cells in anoikis, a form of apoptosis that occurs when cells are denied attachment to the extra-cellular matrix. IGF-I protects mouse embryo fibroblasts (MEF) from anoikis caused by withdrawal of growth factors. Survival is dependent on the concentration of IGF-I and a sufficient number of functional IGF-I receptors. In this model, IGF-I protection correlates best with ras activation and cell-to-cell aggregation, while PI3-kinase, Akt and MAP kinases seem to play a lesser, alternative role.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086337     DOI: 10.1038/sj.onc.1202471

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal.

Authors:  M Le Gall; J C Chambard; J P Breittmayer; D Grall; J Pouysségur; E Van Obberghen-Schilling
Journal:  Mol Biol Cell       Date:  2000-03       Impact factor: 4.138

2.  Altered expression of type I insulin-like growth factor receptor in Crohn's disease.

Authors:  F El Yafi; R Winkler; P Delvenne; N Boussif; J Belaiche; E Louis
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

3.  The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.

Authors:  Matthew J Martin; Nataliya Melnyk; Michelle Pollard; Mary Bowden; Hon Leong; Thomas J Podor; Martin Gleave; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

4.  Transcriptional repression by RB-E2F and regulation of anchorage-independent survival.

Authors:  J T Yu; R G Foster; D C Dean
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

5.  IPF pathogenesis is dependent upon TGFβ induction of IGF-1.

Authors:  Danielle M Hernandez; Jeong-Han Kang; Malay Choudhury; Mahefatiana Andrianifahanana; Xueqian Yin; Andrew H Limper; Edward B Leof
Journal:  FASEB J       Date:  2020-02-17       Impact factor: 5.191

Review 6.  IGF-I receptor, cell-cell adhesion, tumour development and progression.

Authors:  Loredana Mauro; Eva Surmacz
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

7.  Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination.

Authors:  Joanna Trojanek; Thu Ho; Luis Del Valle; Michal Nowicki; Jin Ying Wang; Adam Lassak; Francesca Peruzzi; Kamel Khalili; Tomasz Skorski; Krzysztof Reiss
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

8.  Long-term IGF-I exposure decreases autophagy and cell viability.

Authors:  Alessandro Bitto; Chad Lerner; Claudio Torres; Michaela Roell; Marco Malaguti; Viviana Perez; Antonello Lorenzini; Silvana Hrelia; Yuji Ikeno; Michelle Elizabeth Matzko; Roger McCarter; Christian Sell
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

9.  PTK6 regulates IGF-1-induced anchorage-independent survival.

Authors:  Hanna Y Irie; Yashaswi Shrestha; Laura M Selfors; Fabianne Frye; Naoko Iida; Zhigang Wang; Lihua Zou; Jun Yao; Yiling Lu; Charles B Epstein; Sridaran Natesan; Andrea L Richardson; Kornelia Polyak; Gordon B Mills; William C Hahn; Joan S Brugge
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

10.  The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.

Authors:  D Sachdev; X Zhang; I Matise; M Gaillard-Kelly; D Yee
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.